| P50 | author | Zoltán Varga | Q60678028 |
| P2093 | author name string | György Kéri | |
| | George Mosialos | |
| | László Őrfi | |
| | Zoltán Őrfi | |
| | Frigyes Waczek | |
| | Vassilis Mavromatidis | |
| P2860 | cites work | Targeting Src family kinases in anti-cancer therapies: turning promise into triumph | Q27025646 |
| | Protein kinases--the major drug targets of the twenty-first century? | Q29615339 |
| | Identification of a novel inhibitor of mitogen-activated protein kinase kinase | Q29616448 |
| | Epstein-Barr virus: 40 years on | Q29617969 |
| | Genetic analysis of B cell antigen receptor signaling | Q33652515 |
| | Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. | Q33733617 |
| | EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway | Q33739672 |
| | Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency | Q33784647 |
| | Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A | Q33794029 |
| | Targeting B-cell anergy in chronic lymphocytic leukemia. | Q53117813 |
| | Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173 | Q53291157 |
| | Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells | Q61522646 |
| | Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I | Q73022511 |
| | The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. | Q34014364 |
| | Activation and serine phosphorylation of the p56lck protein tyrosine kinase in response to antigen receptor cross-linking in B lymphocytes | Q34333237 |
| | Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase | Q34344427 |
| | Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells | Q34366291 |
| | An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking | Q35000168 |
| | Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. | Q35832104 |
| | Mechanisms of B-cell lymphoma pathogenesis | Q36085626 |
| | Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival | Q36141691 |
| | Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation | Q36564433 |
| | Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes | Q36646940 |
| | LMP1 TRAFficking activates growth and survival pathways | Q36882628 |
| | The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. | Q37350748 |
| | Off-target effects of MEK inhibitors | Q37385007 |
| | Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. | Q37415623 |
| | Protein kinase inhibitors: contributions from structure to clinical compounds | Q37417742 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders | Q38011765 |
| | Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells. | Q38331064 |
| | The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma | Q39171041 |
| | Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia | Q39725899 |
| | Establishment in continuous culture of a new type of lymphocyte from a “burkitt-like” malignant lymphoma (line d.g.-75) | Q40039870 |
| | Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma | Q40284461 |
| | Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation | Q41068635 |
| | Expression of p56lck in B-cell neoplasias | Q41095204 |
| | Identification of MEK1 as a novel target for the treatment of neuropathic pain | Q42267806 |
| | Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals | Q44664210 |
| | Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases | Q45783522 |
| | A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection | Q46598536 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| P304 | page(s) | e95688 | |
| P577 | publication date | 2014-04-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell lines | |
| P478 | volume | 9 | |